GENERAL CLINICAL RESEARCH CENTER

全科临床研究中心

• 批准号: 2797074
• 负责人: Louis Maximilian BUJA
• 金额: $ 105.72万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
• 依托单位国家: 美国
• 财政年份: 1985
• 资助国家: 美国
• 起止时间: 1985-09-01 至 2000-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2797074
• 关键词: clinical research; human subject

The Clinical Research Center at the University of Texas Health Science Center and Hermann Hospital provides a unique environment for clinical investigation. The faculty of the UT Medical School and UT M.D. Anderson Cancer Center appreciate the advantage and importance of having this multidisciplinary facility which provides meticulous control of experimental conditions, accurate monitoring of biologic phenomena, and proper collection and handling of valuable specimens. Major research areas will include: 1. Analysis of human macrophage function in response to fibrogenic particulates. 2. Use of 177-Lu-CC49 plus alpha interferon in patients with advanced or recurrent ovarian cancer. 3. Elucidation of genetic molecular factors responsible for familial aortic aneurysms. 4. Intraperitoneal priming with rIFNgamma followed by rlL-2 for ex vivo expansion of activated tumor infiltrating lymphocytes in immunotherapy of epithelial ovarian cancer. 5. Elucidation of effects of HIV on growth and development of hemophilic children, adolescents, and young adults. 6. Elucidation of mechanisms of infectivity of Cryptosporidium parvum for adult humans. 7. Characterization of diffuse infiltrating lymphocytosis syndrome (DILS) and its prognosis in patients with HIV infection. 8. Gene therapy in humans and the use of safety-modified retroviruses to introduce chemotherapy resistance sequences for chemoprotection during the therapy of ovarian cancer In our Clinical Research Center (CRC), we wish to conduct meaningful clinical research that elucidate basic mechanisms responsible for human disease leading to improved therapies. We wish to address important diseases and disease processes that affect children and adults with the expectation that the new insights our research provides will contribute to eradication and prevention of serious medical problems. Our CRC will combine clinical research efforts at the University of Texas Medical School and the University of Texas M.D. Anderson Cancer Center at Houston. We anticipate that this combined research effort will lead o new mechanism based therapies that help cure and ultimately prevent selected medical diseases.

德克萨斯大学健康科学临床研究中心 中心和赫尔曼医院为临床提供了独特的环境 调查。 UT 医学院和 UT M.D. Anderson 的教职人员 癌症中心认识到拥有此功能的优势和重要性 多学科设施提供细致的控制 实验条件，生物现象的准确监测，以及 正确收集和处理有价值的标本。主要研究 领域将包括： 1. 人类巨噬细胞对纤维化反应的功能分析 颗粒物。 2. 177-Lu-CC49加α干扰素在晚期患者中的应用 或复发性卵巢癌。 3. 阐明家族遗传的分子因素 主动脉瘤。 4. 腹腔内用 rIFNgamma 启动，然后用 rIL-2 进行离体 免疫治疗中激活的肿瘤浸润淋巴细胞的扩增 上皮性卵巢癌。 5. 阐明HIV对血友病患者生长发育的影响 儿童、青少年和年轻人。 6. 阐明小隐孢子虫的感染机制 对于成年人来说。 7. 弥漫性浸润性淋巴细胞增多症的特征 (DILS) 及其 HIV 感染患者的预后。 8. 人类基因治疗和安全改良逆转录病毒的使用 引入化疗耐药序列以进行化疗保护 卵巢癌的治疗 在我们的临床研究中心 (CRC)，我们希望开展有意义的研究 阐明人类基本机制的临床研究 疾病导致治疗方法的改进。我们希望解决重要的问题 影响儿童和成人的疾病和疾病过程 期望我们的研究提供的新见解将有所贡献 消除和预防严重的医疗问题。我们的CRC将 结合德克萨斯大学医学院的临床研究工作 学校和德克萨斯大学 M.D. 安德森癌症中心 休斯顿。我们预计，这项联合研究工作将带来新的成果 基于机制的疗法有助于治愈并最终预防选定的疾病 医疗疾病。